The relationship between diabetes and dementia has become an increasingly important focus of medical research. Scientists are discovering that problems with blood sugar regulation affect far more than the heart, kidneys, and blood vessels—they also appear to influence how the brain ages. Growing evidence suggests that effective diabetes treatment may help protect memory and thinking later in life.
Diabetes Significantly Increases Dementia Risk
Large population studies have shown that people with type 2 diabetes are approximately 60% more likely to develop dementia than those without the condition.
Both Alzheimer’s disease and vascular dementia, which results from impaired blood flow to the brain, occur more frequently among people with long-standing diabetes.
Repeated episodes of severe hypoglycaemia, or dangerously low blood sugar, may further increase the risk of cognitive decline. While low blood sugar can directly damage brain cells, prolonged exposure to high blood sugar contributes to inflammation and blood vessel injury, together accelerating brain aging.
Insulin Resistance Reaches the Brain
A defining feature of type 2 diabetes is insulin resistance, in which the body’s cells become less responsive to insulin. As a result, glucose remains in the bloodstream, forcing the pancreas to produce increasing amounts of insulin until blood sugar levels begin to rise.
Researchers now know that insulin resistance also affects the brain.
Neurons require insulin to efficiently use glucose as their primary energy source. When insulin signaling becomes impaired, brain cells may struggle to produce enough energy to function properly, potentially contributing to memory impairment and cognitive decline.
Why Some Researchers Call Alzheimer’s “Type 3 Diabetes”
Although the brain accounts for only about 2% of body weight, it consumes roughly 20% of the body’s total energy.
Brain imaging studies have shown that many people with Alzheimer’s disease exhibit reduced glucose metabolism even during the earliest stages of the disease.
Because Alzheimer’s is associated with both impaired glucose use and insulin resistance within the brain, some researchers have informally referred to it as “type 3 diabetes.”
While this is not an officially recognized medical diagnosis, the term reflects growing evidence that metabolic health and brain health are closely connected.
The Relationship May Work Both Ways
Research suggests that diabetes and Alzheimer’s disease may influence each other.
People with Alzheimer’s often have elevated fasting blood glucose levels even if they have never been diagnosed with diabetes. This pattern resembles prediabetes and may increase the likelihood of developing type 2 diabetes.
Animal studies have also suggested that Alzheimer’s-related brain changes can interfere with the body’s regulation of blood sugar.
Researchers have further found that APOE4—the strongest known genetic risk factor for late-onset Alzheimer’s disease—may reduce insulin sensitivity by trapping insulin receptors inside cells.
Blood Vessel Damage and Inflammation
The harmful effects of diabetes on blood vessels extend beyond the heart, kidneys, and eyes.
Persistently elevated or fluctuating blood sugar can damage the delicate blood vessels that supply the brain, reducing oxygen and nutrient delivery.
Diabetes may also weaken the blood-brain barrier, the protective structure that normally prevents harmful substances from entering brain tissue.
When this barrier becomes compromised, inflammatory molecules and toxins can more easily enter the brain, contributing to the chronic inflammation associated with both Alzheimer’s disease and vascular dementia.
Diabetes Drugs Are Being Studied for Brain Health
The growing overlap between diabetes and dementia research has already influenced drug development.
Memantine, which is now widely prescribed for moderate to severe Alzheimer’s disease, was originally developed as a treatment for diabetes. Although it did not effectively lower blood sugar, researchers later discovered that it could help protect neurons and improve cognitive function.
This unexpected path illustrates how targeting metabolism and cellular energy use may benefit both the brain and the rest of the body.
Today, several newer diabetes medications are also being investigated for their potential to slow cognitive decline.
Metformin May Offer Additional Benefits
Metformin remains the most commonly prescribed oral medication for type 2 diabetes.
In addition to improving insulin sensitivity and reducing glucose production in the liver, research suggests that metformin reaches the brain and may reduce inflammation.
Several observational studies have found that people with diabetes who take metformin for extended periods appear less likely to develop dementia than individuals using some other diabetes treatments.
Some evidence also suggests that dementia risk may increase after discontinuing metformin, prompting clinical trials evaluating the medication in people who do not have diabetes.
GLP-1 Drugs Are Now Being Tested
GLP-1 receptor agonists—including semaglutide, marketed under brand names such as Ozempic and Wegovy—were originally developed to treat type 2 diabetes and obesity.
Medical records indicate that people with diabetes taking these medications appear less likely to develop dementia than those receiving certain other treatments.
Some studies have even suggested that GLP-1 therapies may provide greater protection than metformin.
Large clinical trials known as Evoke and Evoke Plus are currently investigating whether oral semaglutide can slow memory decline in people with mild cognitive impairment or early Alzheimer’s disease.
Intranasal Insulin and Other Emerging Treatments
Because insulin resistance within the brain is increasingly viewed as a potential driver of cognitive decline, researchers have also explored delivering insulin directly to the brain through the nasal passages.
This intranasal approach is designed to bypass the bloodstream and target the brain while minimizing effects on blood sugar elsewhere in the body.
Small clinical studies have reported modest improvements in memory and slower brain shrinkage in some participants.
However, results have been mixed, delivery devices vary in effectiveness, and larger clinical trials are still needed to determine long-term safety and clinical benefit.
Another promising group of medications is the SGLT2 inhibitor class.
These drugs lower blood sugar by increasing the amount of glucose excreted in urine.
Recent research suggests that among people with type 2 diabetes, SGLT2 inhibitors may reduce dementia risk even more than GLP-1 receptor agonists, including the risk of both Alzheimer’s disease and vascular dementia.
Scientists believe these benefits may result from reduced inflammation, improved blood vessel function, lower blood pressure, and favorable effects on brain metabolism.
Protecting Both Brain and Body
Although many questions remain, the growing body of research suggests that effective diabetes management may help preserve cognitive function as well as reduce cardiovascular and kidney complications.
Maintaining healthy blood sugar levels, avoiding repeated episodes of severe hypoglycaemia, and controlling blood pressure and cholesterol all appear to play important roles in supporting long-term brain health.
Researchers are still investigating whether diabetes medications can help reduce dementia risk in people without diabetes. Nevertheless, the success of multiple diabetes drug classes and dozens of approved medications demonstrates that targeting metabolism and inflammation may become an important strategy for slowing brain aging.
For now, experts recommend early diagnosis and careful treatment of type 2 diabetes alongside regular physical activity, a balanced diet, good sleep, smoking avoidance, and ongoing medical care. Together, these measures currently offer the strongest evidence-based approach to protecting both the brain and the rest of the body throughout aging.
